ES3029608T1 - Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 - Google Patents

Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 Download PDF

Info

Publication number
ES3029608T1
ES3029608T1 ES20811359T ES20811359T ES3029608T1 ES 3029608 T1 ES3029608 T1 ES 3029608T1 ES 20811359 T ES20811359 T ES 20811359T ES 20811359 T ES20811359 T ES 20811359T ES 3029608 T1 ES3029608 T1 ES 3029608T1
Authority
ES
Spain
Prior art keywords
quinolin
pyrazol
acetamide
pyridin
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES20811359T
Other languages
English (en)
Spanish (es)
Inventor
Artal Ramón Bosser
CASAL Begoña PAMPIN
Laria Julio Castro Palomino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agomab Spain S L U
Original Assignee
Agomab Spain S L U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agomab Spain S L U filed Critical Agomab Spain S L U
Publication of ES3029608T1 publication Critical patent/ES3029608T1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ES20811359T 2019-11-28 2020-11-27 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 Pending ES3029608T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19383057 2019-11-28
PCT/EP2020/083566 WO2021105317A1 (en) 2019-11-28 2020-11-27 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Publications (1)

Publication Number Publication Date
ES3029608T1 true ES3029608T1 (en) 2025-06-24

Family

ID=68808255

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20811359T Pending ES3029608T1 (en) 2019-11-28 2020-11-27 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Country Status (16)

Country Link
US (2) US12297186B2 (https=)
EP (1) EP4065572A1 (https=)
JP (2) JP7808032B2 (https=)
KR (1) KR20220107180A (https=)
CN (1) CN114787145B (https=)
AR (1) AR120578A1 (https=)
AU (1) AU2020394531A1 (https=)
BR (1) BR112022010251A2 (https=)
CA (1) CA3160963A1 (https=)
ES (1) ES3029608T1 (https=)
IL (1) IL293388B2 (https=)
MX (1) MX2022005843A (https=)
PH (1) PH12022551177A1 (https=)
SA (1) SA522432749B1 (https=)
WO (1) WO2021105317A1 (https=)
ZA (1) ZA202205149B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3978487A1 (en) 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
TW202543626A (zh) 2024-02-22 2025-11-16 西班牙商亞哥邁伯西班牙有限公司 新穎結晶相形式

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3621540A1 (de) 1986-06-27 1988-01-07 Basf Ag Chinolinderivate, verfahren zu ihrer herstellung, diese enthaltende mikrobizide und ihre verwendung zur bekaempfung von bakterien und pilzen
JP2004521915A (ja) * 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ過剰発現に対するピラゾール誘導体
HRP20050247A2 (en) 2002-09-18 2005-10-31 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2004026302A1 (en) * 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CN102056907B (zh) 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
AR079545A1 (es) 2009-12-21 2012-02-01 Bayer Cropscience Ag Tienilpiri(mi)dinilazol
DK2731949T3 (en) * 2011-07-13 2018-06-14 Tiumbio Co Ltd 2-PYRIDYL-SUBSTITUTED IMIDAZOLS AS ALK5 AND / OR ALK4 INHIBITORS
US11021468B2 (en) * 2015-04-01 2021-06-01 Rigel Pharmaceuticals, Inc. TGF-ß inhibitors
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
JP2021518855A (ja) 2018-03-02 2021-08-05 ユニヴェルシテ ド ローザンヌ Ｗｎｔシグナル伝達経路阻害剤としてのピラゾール誘導体
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
CN110433164A (zh) * 2019-08-15 2019-11-12 南开大学 TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用
EP3978487A1 (en) 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Also Published As

Publication number Publication date
IL293388B1 (en) 2025-12-01
JP2023504795A (ja) 2023-02-07
AR120578A1 (es) 2022-02-23
IL293388A (en) 2022-07-01
WO2021105317A1 (en) 2021-06-03
CA3160963A1 (en) 2021-06-03
IL293388B2 (en) 2026-04-01
EP4065572A1 (en) 2022-10-05
PH12022551177A1 (en) 2024-02-05
US20230025933A1 (en) 2023-01-26
US12297186B2 (en) 2025-05-13
ZA202205149B (en) 2025-06-25
JP7808032B2 (ja) 2026-01-28
CN114787145A (zh) 2022-07-22
BR112022010251A2 (pt) 2022-09-06
SA522432749B1 (ar) 2025-05-12
KR20220107180A (ko) 2022-08-02
MX2022005843A (es) 2022-07-19
JP2025163046A (ja) 2025-10-28
AU2020394531A1 (en) 2022-06-09
US20250333395A1 (en) 2025-10-30
CN114787145B (zh) 2024-03-26

Similar Documents

Publication Publication Date Title
PE20252775A1 (es) Compuestos de pirido[4,3-d]pirimidina
ES2525429T3 (es) Inhibidores de la proteína tirosina fosfatasa humana y métodos de uso
AU2021231064B2 (en) Treatment of pain and vasoconstriction
JP2013139472A (ja) 置換アシルアニリドおよびそれらの使用方法
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний
JP2017523225A5 (https=)
JP2010532383A5 (https=)
ES3029608T1 (en) Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
MX2020002429A (es) Compuestos para reducir la viscosidad de las formulaciones biologicas.
MX2024015961A (es) Compuesto de 3,4-dihidroquinolin-2 (1h)-ona
JP2024095711A (ja) 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール
JP2012522805A5 (https=)
US10485786B2 (en) Pharmaceutical composition for preventing or treating macular degeneration
ES3029607T1 (en) 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
RU2010151143A (ru) Замещенные хиназолины
ES2573295T3 (es) Combinaciones farmacéuticas que comprenden un inhibidor de Hsp90 derivado de isoxazol y el inhibidor de HER2 trastuzumab
WO2022034909A1 (ja) セペタプロストを含有する医薬製剤
TW200914008A (en) Raf inhibitors for the treatment of thyroid cancer
CO2024002712A2 (es) Azálidos inmunomoduladores
AU2020264969B2 (en) Tie-2 activators targeting the schlemm's canal
RU2019104928A (ru) Производное индола, используемое в качестве ингибитора CRTH2
JPWO2021105317A5 (https=)
JP2014521647A5 (https=)
WO2019124487A1 (ja) オミデネパグの組合せ
NZ739077B2 (en) Il-8 inhibitors for use in the treatment of certain urological disorders